Asahi Kasei completed the acquisition of Calliditas Therapeutics for $1.1bn.

Synopsis

Asahi Kasei, a multinational Japanese chemicals company, completed the acquisition of Calliditas Therapeutics, a commercial stage biopharmaceutical company, for $1.1bn.

Principals

target

Calliditas Therapeutics

bidder

Asahi Kasei Corporation

Show Details & Financials

Did you work on this deal?

Showcase your expertise to over 3 million dealmakers and industry leaders on Datasite.

Market Context

Dealmakers

Service Providers (5)

15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.